BIIB Jan 2026 155.000 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

11.70

0.00

(0.00%)

At close: 11:14AM EDT

Loading interactive chart...

Zacks
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Zacks
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
Zacks
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.